Treatment of reflux among drugs added to PBS



Medicines for a host of conditions will be newly subsidized starting in October, potentially generating $130 million in direct savings.

Patients will soon have access to cheaper drugs for migraines, psoriatic arthritis, breast cancer, stomach ulcers and bipolar disorder.

Patients will soon have access to cheaper drugs for migraines, psoriatic arthritis, breast cancer, stomach ulcers and bipolar disorder, after the federal government announced additions to the PBS starting next month .

The changes, which come into effect on October 1, are expected to result in more than $130 million in savings for Australian patients and nearly $930 million in savings for taxpayers, according to a Department of Health and Welfare. Elderly care. (DoH) release.

“Listing these medicines on the PBS will improve the lives of thousands of Australian patients and their families,” said Federal Minister for Health and Aged Care Mark Butler.

‘We will do it [also] reduce the cost of medicines for millions of Australians by reducing the PBS co-payment from the current maximum of $42.50 per script, to a maximum of $30 per script from 1 January 2023.’

Up to 500,000 patients with stomach ulcers or gastroesophageal reflux disease will pay a maximum of $26.74 per script for esomeprazole 40mg tablets, a savings of up to $6.84, according to the release. $ per script.

Other additions will see:

  • more than 60,000 patients with schizophrenia or bipolar disorder had access to scenarios for quetiapine tablets 200mg at a cost of $28.42, saving up to $6.22 per scenario
  • over 20,000 migraine and epilepsy sufferers pay $34.90 per script for 200mg topiramate tablets, a savings of up to $6.63. Similarly, scripts for Lamotrigine 200mg anti-epileptic tablets will cost $33.45, which is a savings of up to $4.66.
  • approximately 15,000 patients with severe psoriatic arthritis who are prescribed leflunomide 20mg tablets paying $37.19 per script, saving up to $5.31 per script
  • women using anastrozole to inhibit breast cancer progression saving up to $2.36 per script. About 13,000 patients a year can now expect to pay $22.07 per script for a 1mg tablet.

Drugs aimed at treating types of cancer and growth hormone deficiency in children will also be added, including pembrolizumab (sold as Keytruda), which will be expanded to treat patients with squamous cell carcinoma of the head and by the neck.

An average of 500 patients per year could benefit from this expanded list, without which they would face more than $135,000 in medical costs per treatment.

The announcement came the same day Minister Butler promoted a plan to reduce the price of everyday drugs.

Minister Butler said the bill, which will be debated in Parliament this week, could be the trigger for the “biggest reduction in the cost of medicines for Australian households in the 75-year history of the Pharmaceutical Benefits Scheme”.

“It’s not just good for the hip pouches of millions of Australian patients,” he said.

“It’s also good for their health, because abs [Australian Bureau of Statistics] told us that up to 900,000 Australians every year choose to go without the medicines their doctor has prescribed for their health.

‘And pharmacist after pharmacist has told me stories of customers walking into their pharmacy and putting a number of scripts on their counter asking for advice on which ones they can go without because they can’t afford to fill in all the scripts.

“I look forward to the debate in the House and then in the Senate [about] this important legislation.

More information on drugs to be on the PBS list is available on line.

Log in below to join the conversation.

cancer epilepsy migraine PBS Pharmaceutical Benefits Scheme psoriatic arthritis reflux

newsGP weekly poll
Have you been the victim of violence from patients in the context of your work as a general practitioner?


Comments are closed.